CATT of course tested ranibizumab (Lucentis) as the control against bevacizumab (Avastin) and not aflibercept (Eylea) against bevacizumab (Lucentis).
Apologies. I was too late to edit my above post.
Ann: Opthea to Host Key Opinion Leader Event on April 3, 2024, page-37
Add OPT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
36.0¢ |
Change
-0.005(1.37%) |
Mkt cap ! $245.2M | |||
| Open | High | Low | Value | Volume |
| 36.5¢ | 37.5¢ | 36.0¢ | $451.8K | 1.234M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 15 | 714959 | 36.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 36.5¢ | 313299 | 9 |
View Market Depth
| Last trade - 12.07pm 17/06/2024 (20 minute delay) ? |
|
|||||
|
Last
36.5¢ |
Change
-0.005 ( 1.43 %) |
||||
| Open | High | Low | Volume | ||
| 36.5¢ | 37.0¢ | 36.0¢ | 775263 | ||
| Last updated 12.30pm 17/06/2024 ? | |||||
| OPT (ASX) Chart |
